Method of treating cancer with a fully myeloablative regimen of

Details Method of treating cancer with a fully myeloablative regimen of Method of treating cancer with a fully myeloablative regimen of

1995-05-26

1997-07-22

McDermott, Corrine M.

Surgery

Blood drawn and replaced or treated and returned to body

128898, 530351, 604 49, A61M 3700

Patent

active

056499043

ABSTRACT:
The use, in sequence, of a cytotoxic, but stem cell sparing, agent and granulocyte-macrophage colony stimulating factor as a means to harvest very high numbers of multipotential haemopoietic precursor cells and in reducing the period of myeloid recovery after high dose chemo- or radiotherapy of cancer.

REFERENCES:
patent: 4778879 (1988-10-01), Mertelsmann
patent: 4863902 (1989-09-01), Amagase
patent: 4898818 (1990-02-01), Nakai
patent: 4908433 (1990-03-01), Mertelsmann
patent: 5008374 (1991-04-01), Nakai
Brandt et al., N. Engl. J. Med. 318, 869-876 (1988). (Apr. 07).
Gabrilove et al., N. Engl. J. Med. 318, 1414-1422 (1988). (Jun. 02).
Gianni et al., Hematolog. Oncol. 7, 139-148 (1989).
Gianni et al., Lancet 1989, 580-584. (Sep. 09).
Gianni et al., Bone Marrow Transplant. 6, 143-145 (1990).
Socinski et al., Lancet 1988, 1194-1198 (May 28).
Tilly et al., Leukemia Research 10, 353-356 (1986).
To et al., Brit. J. Haematol. 58, 399-410 (1984).
Nakai et al. "The Therapeutic Potential of IL-1B in the Treatment of Chemotherapy Radiation Induced Myelosuppresion in Tumor Therapy" Biotherapy, vol. 1 #4, 1989, pp. (339-354-abstract only).
Steward et al. "Recombinant Human Granulocyte Macrophage Stimulating Factor with GM-CSF Given as Daily Short Infusions: a Phase One Dose Toxicity Stud" British Jrnl. of Cancer, vol. 59 #1, 11989 (abstract only).
Mertelsmann et al. "Prevention of Chemically Induced Neutropenia and Associated Morbidity . . . GM-CSF" 18 Annual Mtg. of American Ass. for Cancer Research, May 24-27, 1989.
Ganser et al. "Chemical Effects of Recombinant Human 16-3" American Jrnl of Clinical Oncology, vol. 14, suppl., 1991, pp. 951-956 (abstract only).

Affiliated with

Also associated with

Rating

Method of treating cancer with a fully myeloablative regimen of does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Method of treating cancer with a fully myeloablative regimen of , we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treating cancer with a fully myeloablative regimen of will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1557163